Search

Your search keyword '"Warren, Robin M."' showing total 330 results
Start Over Author "Warren, Robin M." Search Limiters Peer Reviewed
330 results on '"Warren, Robin M."'

6. Bedaquiline: what might the future hold?

Author

Shaw, Emily S, Stoker, Neil G, Potter, Jessica L, Claassen, Helgard, Leslie, Alasdair, Tweed, Conor D, Chiang, Chen-Yuan, Conradie, Francesca, Esmail, Hanif, Lange, Christoph, Pinto, Lancelot, Rucsineanu, Oxana, Sloan, Derek J, Theron, Grant, Tisile, Phumeza, Voo, Teck Chuan, Warren, Robin M, Lebina, Limakatso, and Lipman, Marc

Published
2024
Full Text
View/download PDF

8. Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy study

Author

Reeve, Byron W P, Ndlangalavu, Gcobisa, Mishra, Hridesh, Palmer, Zaida, Tshivhula, Happy, Rockman, Loren, Naidoo, Selisha, Mbu, Desiree L, Naidoo, Charissa C, Derendinger, Brigitta, Walzl, Gerhard, Malherbe, Stephanus T, van Helden, Paul D, Semitala, Fred C, Yoon, Christina, Gupta, Rishi K, Noursadeghi, Mahdad, Warren, Robin M, and Theron, Grant

Published
2024
Full Text
View/download PDF

11. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis

Author

Walker, A Sarah, Steyn, Adrie J C, Lalvani, Ajit, Baulard, Alain, Christoffels, Alan, Mendoza-Ticona, Alberto, Trovato, Alberto, Skrahina, Alena, Lachapelle, Alexander S, Brankin, Alice, Piatek, Amy, Gibertoni Cruz, Ana, Koch, Anastasia, Cabibbe, Andrea Maurizio, Spitaleri, Andrea, Brandao, Angela P, Chaiprasert, Angkana, Suresh, Anita, Barbova, Anna, Van Rie, Annelies, Ghodousi, Arash, Bainomugisa, Arnold, Mandal, Ayan, Roohi, Aysha, Javid, Babak, Zhu, Baoli, Letcher, Brice, Rodrigues, Camilla, Nimmo, Camus, NATHANSON, Carl-Michael, Duncan, Carla, Coulter, Christopher, Utpatel, Christian, Liu, Chunfa, Grazian, Clara, Kong, Clare, Köser, Claudio U, Wilson, Daniel J, Cirillo, Daniela Maria, Matias, Daniela, Jorgensen, Danielle, Zimenkov, Danila, Chetty, Darren, Moore, David AJ, Clifton, David A, Crook, Derrick W, van Soolingen, Dick, Liu, Dongxin, Kohlerschmidt, Donna, Barreira, Draurio, Ngcamu, Dumisani, Santos Lazaro, Elias David, Kelly, Ellis, Borroni, Emanuele, Roycroft, Emma, Andre, Emmanuel, Böttger, Erik C, Robinson, Esther, Menardo, Fabrizio, Mendes, Flavia F, Jamieson, Frances B, Coll, Francesc, Gao, George Fu, Kasule, George W, Rossolini, Gian Maria, Rodger, Gillian, Smith, E Grace, Meintjes, Graeme, Thwaites, Guy, Hoffmann, Harald, Albert, Heidi, Cox, Helen, Laurenson, Ian F, Comas, Iñaki, Arandjelovic, Irena, Barilar, Ivan, Robledo, Jaime, Millard, James, Johnston, James, Posey, Jamie, Andrews, Jason R, Knaggs, Jeff, Gardy, Jennifer, Guthrie, Jennifer, Taylor, Jill, Werngren, Jim, Metcalfe, John, Coronel, Jorge, Shea, Joseph, Carter, Joshua, Pinhata, Juliana MW, Kus, Julianne V, Todt, Katharina, Holt, Kathryn, Nilgiriwala, Kayzad S, Ghisi, Kelen T, Malone, Kerri M, Faksri, Kiatichai, Musser, Kimberlee A, Joseph, Lavania, Rigouts, Leen, Chindelevitch, Leonid, Jarrett, Lisa, Grandjean, Louis, Ferrazoli, Lucilaine, Rodrigues, Mabel, Farhat, Maha, Schito, Marco, Fitzgibbon, Margaret M, Loembé, Marguerite Massinga, Wijkander, Maria, Ballif, Marie, Rabodoarivelo, Marie-Sylvianne, Mihalic, Marina, WILCOX, Mark, Hunt, Martin, ZIGNOL, Matteo, Merker, Matthias, Egger, Matthias, O'Donnell, Max, Caws, Maxine, Wu, Mei-Hua, Whitfield, Michael G, Inouye, Michael, Mansjö, Mikael, Dang Thi, Minh Ha, Joloba, Moses, Kamal, SM Mostofa, Okozi, Nana, ISMAIL, Nazir, Mistry, Nerges, Hoang, Nhung N, Rakotosamimanana, Niaina, Paton, Nicholas I, Rancoita, Paola M V, Miotto, Paolo, Lapierre, Pascal, Hall, Patricia J, Tang, Patrick, Claxton, Pauline, Wintringer, Penelope, Keller, Peter M, Thai, Phan Vuong Khac, Fowler, Philip W, Supply, Philip, Srilohasin, Prapaporn, Suriyaphol, Prapat, Rathod, Priti, Kambli, Priti, Groenheit, Ramona, Colman, Rebecca E, Ong, Rick Twee-Hee, Warren, Robin M, Wilkinson, Robert J, Diel, Roland, Oliveira, Rosangela S, Khot, Rukhsar, Jou, Ruwen, Tahseen, Sabira, Laurent, Sacha, Gharbia, Saheer, Kouchaki, Samaneh, Shah, Sanchi, Plesnik, Sara, Earle, Sarah G, Dunstan, Sarah, Hoosdally, Sarah J, Mitarai, Satoshi, Gagneux, Sebastien, Omar, Shaheed V, Yao, Shen-Yuan, Grandjean Lapierre, Simon, Battaglia, Simone, Niemann, Stefan, Pandey, Sushil, Uplekar, Swapna, Halse, Tanya A, Cohen, Ted, Cortes, Teresa, Prammananan, Therdsak, Kohl, Thomas A, Thuong, Nguyen T T, Teo, Tik Ying, Peto, Timothy E A, Rodwell, Timothy C, William, Timothy, Walker, Timothy M, Rogers, Thomas R, Surve, Utkarsha, Mathys, Vanessa, Furió, Victoria, Cook, Victoria, Vijay, Srinivasan, Escuyer, Vincent, Dreyer, Viola, Sintchenko, Vitali, Saphonn, Vonthanak, Solano, Walter, Lin, Wan-Hsuan, van Gemert, Wayne, He, Wencong, Yang, Yang, Zhao, Yanlin, Qin, Youwen, Xiao, Yu-Xin, Hasan, Zahra, Iqbal, Zamin, Puyen, Zully M, Farhat, Maha R, Posey, James, Peto, Timothy EA, Nathanson, Carl-Michael, Zignol, Matteo, Walker, Ann Sarah, and Ismail, Nazir

Published
2022
Full Text
View/download PDF

12. The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa.

Author

Klopper, Marisa, van der Merwe, Charnay J., van der Heijden, Yuri F., Folkerts, Megan, Loubser, Johannes, Streicher, Elizabeth M., Mekler, Kate, Hayes, Cindy, Engelthaler, David M., Metcalfe, John Z., and Warren, Robin M.

Subjects
WHOLE genome sequencing, ISONIAZID, TUBERCULOSIS, GENOTYPES, PHENOTYPES
Abstract

Rationale: Isoniazid-resistant tuberculosis (Hr-TB) is often overlooked in diagnostic algorithms because of reliance on first-line molecular assays testing only for rifampicin resistance. Objectives: To determine the prevalence, outcomes, and molecular mechanisms associated with rifampin-susceptible, isoniazid-resistant TB (Hr-TB) in the Eastern Cape, South Africa. Methods: Between April 2016 and October 2017, sputum samples were collected from patients with rifampin-susceptible TB at baseline and at Weeks 7 and 23 of drug-susceptible TB treatment. We performed isoniazid phenotypic and genotypic drug susceptibility testing, including FluoroTypeMTBDR, Sanger sequencing, targeted next-generation sequencing, and whole-genome sequencing. Results: We analyzed baseline isolates from 766 patients with rifampin-susceptible TB. Of 89 patients (11.7%) who were found to have Hr-TB, 39 (44%) had canonical katG or inhA promoter mutations; 35 (39%) had noncanonical katG mutations (including 5 with underlying large deletions); 4 (5%) had mutations in other candidate genes associated with isoniazid resistance. For 11 (12.4%), no cause of resistance was found. Conclusions: Among patients with rifampin-susceptible TB who were diagnosed using first-line molecular TB assays, there is a high prevalence of Hr-TB. Phenotypic drug susceptibility testing remains the gold standard. To improve the performance of genetic-based phenotyping tests, all isoniazid resistance–associated regions should be included, and such tests should have the ability to identify underlying mutations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study

Author

Cox, Helen, Salaam-Dreyer, Zubeida, Goig, Galo A, Nicol, Mark P, Menardo, Fabrizio, Dippenaar, Anzaan, Mohr-Holland, Erika, Daniels, Johnny, Cudahy, Patrick G T, Borrell, Sonia, Reinhard, Miriam, Doetsch, Anna, Beisel, Christian, Reuter, Anja, Furin, Jennifer, Gagneux, Sebastien, and Warren, Robin M

Published
2021
Full Text
View/download PDF

26. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis.

Author

Verboven, Lennert, Callens, Steven, Black, John, Maartens, Gary, Dooley, Kelly E., Potgieter, Samantha, Cartuyvels, Ruben, Laukens, Kris, Warren, Robin M., and Van Rie, Annelies

Subjects
CLINICAL decision support systems, WHOLE genome sequencing, LITERATURE reviews, RIFAMPIN, DIGITAL technology, HIGH-income countries
Abstract

Background: Rifampicin resistant tuberculosis remains a global health problem with almost half a million new cases annually. In high-income countries patients empirically start a standardized treatment regimen, followed by an individualized regimen guided by drug susceptibility test (DST) results. In most settings, DST information is not available or is limited to isoniazid and fluoroquinolones. Whole genome sequencing could more accurately guide individualized treatment as the full drug resistance profile is obtained with a single test. Whole genome sequencing has not reached its full potential for patient care, in part due to the complexity of translating a resistance profile into the most effective individualized regimen. Methods: We developed a treatment recommender clinical decision support system (CDSS) and an accompanying web application for user-friendly recommendation of the optimal individualized treatment regimen to a clinician. Results: Following expert stakeholder meetings and literature review, nine drug features and 14 treatment regimen features were identified and quantified. Using machine learning, a model was developed to predict the optimal treatment regimen based on a training set of 3895 treatment regimen-expert feedback pairs. The acceptability of the treatment recommender CDSS was assessed as part of a clinical trial and in a routine care setting. Within the clinical trial setting, all patients received the CDSS recommended treatment. In 8 of 20 cases, the initial recommendation was recomputed because of stock out, clinical contra-indication or toxicity. In routine care setting, physicians rejected the treatment recommendation in 7 out of 15 cases because it deviated from the national TB treatment guidelines. A survey indicated that the treatment recommender CDSS is easy to use and useful in clinical practice but requires digital infrastructure support and training. Conclusions: Our findings suggest that global implementation of the novel treatment recommender CDSS holds the potential to improve treatment outcomes of patients with RR-TB, especially those with 'difficult-to-treat' forms of RR-TB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.

Author

Wijk, Marie, Gausi, Kamunkhwala, Malatesta, Samantha, Weber, Sarah E, Court, Richard, Myers, Bronwyn, Carney, Tara, Parry, Charles D H, Horsburgh, C Robert, White, Laura F, Wiesner, Lubbe, Warren, Robin M, Uren, Caitlin, McIlleron, Helen, Kloprogge, Frank, Denti, Paolo, and Jacobson, Karen R

Subjects
ALCOHOL drinking, SUBSTANCE abuse, PHARMACOKINETICS, TUBERCULOSIS, ETHAMBUTOL, ISONIAZID
Abstract

Background In South Africa, an estimated 11% of the population have high alcohol use, a major risk factor for TB. Alcohol and other substance use are also associated with poor treatment response, with a potential mechanism being altered TB drug pharmacokinetics. Objectives To investigate the impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs in participants with pulmonary TB. Methods We prospectively enrolled participants ≥15 years old, without HIV, and initiating drug-susceptible TB treatment in Worcester, South Africa. Alcohol use was measured via self-report and blood biomarkers. Other illicit substances were captured through a urine drug test. Plasma samples were drawn 1 month into treatment pre-dose, and 1.5, 3, 5 and 8 h post-dose. Non-linear mixed-effects modelling was used to describe the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol. Alcohol and drug use were tested as covariates. Results The study included 104 participants, of whom 70% were male, with a median age of 37 years (IQR 27–48). Alcohol use was high, with 42% and 28% of participants having moderate and high alcohol use, respectively. Rifampicin and isoniazid had slightly lower pharmacokinetics compared with previous reports, whereas pyrazinamide and ethambutol were consistent. No significant alcohol use effect was detected, other than 13% higher ethambutol clearance in participants with high alcohol use. Methaqualone use reduced rifampicin bioavailability by 19%. Conclusion No clinically relevant effect of alcohol use was observed on the pharmacokinetics of first-line TB drugs, suggesting that poor treatment outcome is unlikely due to pharmacokinetic alterations. That methaqualone reduced rifampicin means dose adjustment may be beneficial. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa

Author

Leavitt, Sarah V., Jacobson, Karen R., Ragan, Elizabeth J., Bor, Jacob, Hughes, Jennifer, Bouton, Tara C., Dolby, Tania, Warren, Robin M., and Jenkins, Helen E.

Subjects
Decentralization (Management) -- Analysis -- Health aspects, Tuberculosis -- Care and treatment, Public health administration -- Methods, Health
Abstract

South Africa has a high tuberculosis (TB) prevalence, complicated by multidrug resistance to rifampin and isoniazid (1). In 2018, multidrug-resistant (MDR) and rifampin-resistant (RR) TB accounted for 3.4% of new [...]

Published
2021
Full Text
View/download PDF

30. Human whole genome sequencing in South Africa

Author

Glanzmann, Brigitte, Jooste, Tracey, Ghoor, Samira, Gordon, Richard, Mia, Rizwana, Mao, Jun, Li, Hao, Charls, Patrick, Douman, Craig, Kotze, Maritha J., Peeters, Armand V., Loots, Glaudina, Esser, Monika, Tiemessen, Caroline T., Wilkinson, Robert J., Louw, Johan, Gray, Glenda, Warren, Robin M., Möller, Marlo, and Kinnear, Craig

Published
2021
Full Text
View/download PDF

36. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis

Author

Dheda, Keertan, Gumbo, Tawanda, Maartens, Gary, Dooley, Kelly E, Esmail, Aliasgar, Murray, Megan, Furin, Jennifer, Nardell, Edward, London, Leslie, Lessem, Erica, Limberis, Jason, Theron, Grant, McNerney, Ruth, Niemann, Stefan, Dowdy, David, Van Rie, Annelies, Pasipanodya, Jotam G, Rodrigues, Camilla, Clark, Taane G, Sirgel, Frik A, Schaaf, H Simon, Chang, Kwok Chiu, Lange, Christoph, Nahid, Payam, Fourie, Bernard, Ndjeka, Norbert, Nunn, Andrew, Migliori, GB, Udwadia, Zarir F, Horsburgh, C Robert, Jr, Churchyard, Gavin J, Menzies, Dick, Hesseling, Anneke C, Seddon, James A, Low, Marcus, Keshavjee, Salmaan, Nuermberger, Eric, McIlleron, Helen, Fennelly, Kevin P, Jindani, Amina, Jaramillo, Ernesto, Padayatchi, Nesri, Barry, Clifton E, 3rd, Warren, Robin M, and Nardell, Edward A

Published
2019
Full Text
View/download PDF

37. Distinct serum biosignatures are associated with different tuberculosis treatment outcomes

Author

Ronacher, Katharina, Chegou, Novel N., Kleynhans, Léanie, Djoba Siawaya, Joel F., du Plessis, Nelita, Loxton, André G., Maasdorp, Elizna, Tromp, Gerard, Kidd, Martin, Stanley, Kim, Kriel, Magdalena, Menezes, Angela, Gutschmidt, Andrea, van der Spuy, Gian D., Warren, Robin M., Dietze, Reynaldo, Okwera, Alphonse, Thiel, Bonnie, Belisle, John T., Cliff, Jacqueline M., Boom, W. Henry, Johnson, John L., van Helden, Paul D., Dockrell, Hazel M., and Walzl, Gerhard

Published
2019
Full Text
View/download PDF

39. Latent Tuberculosis Infection Is Associated with an Enrichment of Short-Chain Fatty Acid-Producing Bacteria in the Stool of Women Living with HIV.

Author

Moodley, Suventha, Kroon, Elouise, Naidoo, Charissa C., Nyawo, Georgina R., Wu, Benjamin G., Naidoo, Selisha, Chiyaka, Tinaye L., Tshivhula, Happy, Singh, Shivani, Li, Yonghua, Warren, Robin M., Hoal, Eileen G., Schurr, Erwin, Clemente, Jose C., Segal, Leopoldo N., Möller, Marlo, and Theron, Grant

Subjects
LATENT tuberculosis, HIV-positive women, SHORT-chain fatty acids, TUBERCULIN test, HIV-positive persons
Abstract

Latent tuberculosis infection (LTBI) is common in people living with HIV (PLHIV) in high-TB-burden settings. Active TB is associated with specific stool taxa; however, little is known about the stool microbiota and LTBI in PLHIV. We characterised the stool microbiota of PLHIV with [interferon-γ release assay (IGRA)- and tuberculin skin test (TST)-positive] or without (IGRA- and TST-negative) LTBI (n = 25 per group). The 16S rRNA DNA sequences were analysed using QIIME2, Dirichlet-Multinomial Mixtures, DESeq2, and PICRUSt2. No α- or β-diversity differences occurred by LTBI status; however, LTBI-positive people were Faecalibacterium-, Blautia-, Gemmiger-, and Bacteroides-enriched and Moryella-, Atopobium-, Corynebacterium-, and Streptococcus-depleted. Inferred metagenome data showed that LTBI-negative-enriched pathways included several metabolite degradation pathways. Stool from LTBI-positive people demonstrated differential taxa abundance based on a quantitative response to antigen stimulation. In LTBI-positive people, older people had different β-diversities than younger people, whereas in LTBI-negative people, no differences occurred across age groups. Amongst female PLHIV, those with LTBI were, vs. those without LTBI, Faecalibacterium-, Blautia-, Gemmiger-, and Bacteriodes-enriched, which are producers of short-chain fatty acids. Taxonomic differences amongst people with LTBI occurred according to quantitative response to antigen stimulation and age. These data enhance our understanding of the microbiome's potential role in LTBI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Author

Dheda, Keertan, Gumbo, Tawanda, Maartens, Gary, Dooley, Kelly E, McNerney, Ruth, Murray, Megan, Furin, Jennifer, Nardell, Edward A, London, Leslie, Lessem, Erica, Theron, Grant, van Helden, Paul, Niemann, Stefan, Merker, Matthias, Dowdy, David, Van Rie, Annelies, Siu, Gilman K H, Pasipanodya, Jotam G, Rodrigues, Camilla, Clark, Taane G, Sirgel, Frik A, Esmail, Aliasgar, Lin, Hsien-Ho, Atre, Sachin R, Schaaf, H Simon, Chang, Kwok Chiu, Lange, Christoph, Nahid, Payam, Udwadia, Zarir F, Horsburgh, C Robert, Jr, Churchyard, Gavin J, Menzies, Dick, Hesseling, Anneke C, Nuermberger, Eric, McIlleron, Helen, Fennelly, Kevin P, Goemaere, Eric, Jaramillo, Ernesto, Low, Marcus, Jara, Carolina Morán, Padayatchi, Nesri, and Warren, Robin M

Published
2017
Full Text
View/download PDF

45. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study

Author

Dheda, Keertan, Limberis, Jason D, Pietersen, Elize, Phelan, Jody, Esmail, Aliasgar, Lesosky, Maia, Fennelly, Kevin P, te Riele, Julian, Mastrapa, Barbara, Streicher, Elizabeth M, Dolby, Tania, Abdallah, Abdallah M, Ben-Rached, Fathia, Simpson, John, Smith, Liezel, Gumbo, Tawanda, van Helden, Paul, Sirgel, Frederick A, McNerney, Ruth, Theron, Grant, Pain, Arnab, Clark, Taane G, and Warren, Robin M

Published
2017
Full Text
View/download PDF

46. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era

Author

Beckert, Patrick, Sanchez-Padilla, Elisabeth, Merker, Matthias, Dreyer, Viola, Kohl, Thomas A., Utpatel, Christian, Köser, Claudio U., Barilar, Ivan, Ismail, Nazir, Omar, Shaheed Vally, Klopper, Marisa, Warren, Robin M., Hoffmann, Harald, Maphalala, Gugu, Ardizzoni, Elisa, de Jong, Bouke C., Kerschberger, Bernhard, Schramm, Birgit, Andres, Sönke, Kranzer, Katharina, Maurer, Florian P., Bonnet, Maryline, and Niemann, Stefan

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results